On November 13, 2026, InspireMD, Inc. announced the pricing of an underwritten public offering. The company agreed to sell 7,342,308 shares of its common stock, par value $0.0001 per share, alongside pre-funded warrants to purchase up to 50,350,000 shares of common stock. Additionally, the company is selling accompanying Series L warrants to purchase up to 43,269,231 shares of common stock.
The offering is being led by Lake Street Capital Markets, LLC, which is acting as the sole book runner. The combined public offering price for the common stock and accompanying warrants is $0.65 per share. The pre-funded warrants are being sold at a combined price of $0.6499 per share, which is equal to the price of the common stock and warrants minus $0.0001.
Under the terms of the agreement, Lake Street Capital Markets will receive an underwriting discount equal to 6.0% of the gross proceeds. The company also granted the underwriters a 30-day option to purchase additional securities. This option allows the underwriters to buy up to 8,653,846 shares of common stock and/or pre-funded warrants and/or common warrants to purchase up to 6,490,384 shares of common stock. This option represents 15% of the total number of securities sold in the offering.
Based on the number of shares and warrants sold at the initial pricing, the company estimates gross proceeds of approximately $37.5 million. If the underwriters exercise their option to purchase additional securities in full, the gross proceeds could increase to approximately $43.1 million. The company intends to use the net proceeds from the offering for research and development, sales and marketing, working capital, and other general corporate purposes.
The closing of the offering is expected to occur on or about November 16, 2026, subject to the satisfaction of customary closing conditions. The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-286309) filed with the SEC on April 1, 2025.